References
- Cogliano V, Grosse Y, Baan R, et al. for the WHO International Agency for Research on Cancer. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005; 6: 552–553
- Stewart B W, Kleihues P. World Cancer Report. IARC Press, Lyon 2003
- Cogliano V, Baan R, Straif K, et al. for the WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6: 204
- Moreno V, Bosch F X, Munoz N, et al. for the International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359: 1085–1092
- Smith J S, Green J, de Gonzalez A B, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361: 1159–1167
- International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cancer from 24 epidemiological studies. Lancet 2007; 370: 1609–1621
- Muñoz N, Franceschi S, Bosetti C, et al. for the International Agency for Research on Cancer (IARC). Multicentric Cervical Cancer Study Group. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002; 359: 1093–1101
- Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer 2006; 95: 385–389
- Hannaford P C, Selvaraj S, Elliott A M, et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007; 335: 651–659
- Maxwell G L, Schildkraut J M, Calingaert B, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol 2006; 103: 535–540
- Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 2008; 371: 303–314
- Editorial. The case for preventing ovarian cancer. Lancet 2008; 371: 275